A Phase 1 Dose Escalation Study of Seneca Valley Virus (SVV-001), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, Ewing Family of Tumors and Rare Tumors With Neuroendocrine Features.

Trial Profile

A Phase 1 Dose Escalation Study of Seneca Valley Virus (SVV-001), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, Ewing Family of Tumors and Rare Tumors With Neuroendocrine Features.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2015

At a glance

  • Drugs NTX 010 (Primary) ; Cyclophosphamide
  • Indications Adrenocortical carcinoma; Carcinoid tumour; Ewing's sarcoma; Neuroblastoma; Renal cancer; Retinoblastoma; Rhabdomyosarcoma; Wilms' tumour
  • Focus Adverse reactions
  • Most Recent Events

    • 23 May 2012 Planned end date changed from 1 Jun 2010 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 23 May 2012 Planned number of patients changed from 34 to 51 as reported by ClinicalTrials.gov.
    • 16 Nov 2010 Added eight new trial locations, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top